[Withdrawal of a drug from the market for safety reasons: process and communication].
Each year, drugs must be withdrawn from the market following the identification of serious adverse reactions. We report here on an enquiry addressed to persons involved in the recent withdrawal of nefazodone, and a survey of physicians and pharmacists. Our results show the complexities of such withdrawal decisions and the difficulty in communicating them through the network of health professionals down to the patients.
Genton
A
A
Division de Pharmacologie et Toxicologie cliniques, Centre Hospitalier Universitaire Vaudois (CHUV).
Buclin
Th
T
D016907:Adverse Drug Reaction Reporting Systems / Q000331:legislation & jurisprudence*; D018687:Antidepressive Agents, Second-Generation / Q000633:toxicity*; D001291:Attitude of Health Personnel; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003142:Communication; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004346:Drug Information Services / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007400:Interprofessional Relations; D010879:Piperazines; D013557:Switzerland; D014230:Triazoles / Q000633:toxicity*
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone